目的：探讨丙戊酸钠缓释片联合阿立哌唑治疗双相障碍躁狂发作的疗效和安全性。方法将81例双相障碍躁狂发作患者按照治疗方法不同分为观察组42例，对照组39例，均口服丙戊酸钠缓释片治疗，观察组联合阿立哌唑治疗，对照组联合喹硫平治疗，观察8周。采用Young躁狂评定量表评定躁狂状况、健康调查简表评定生活质量、匹兹堡睡眠质量指数量表评定睡眠质量、副反应量表评定不良反应。结果治疗后两组Young躁狂评定量表总分及匹兹堡睡眠质量指数量表各维度评分均较治疗前显著下降（P＜0．01），观察组显著低于对照组（P＜0．01）；两组健康调查简表各维度评分均较治疗前显著升高（P＜0．01），观察组显著高于对照组（P＜0．01）。两组不良反应均较轻微，发生率比较差异无显著性（P＞0．05）。结论丙戊酸钠缓释片联合阿立哌唑治疗双相障碍躁狂发作疗效显著，能有效改善患者的生活质量及睡眠质量，安全性高。%Objective To explore the efficacy and safety of sodium valproate sus‐tained release tablets (SVSRT ) plus aripiprazole in the treatment of manic episode of bipolar disorder . Methods Eighty‐one patients with manic episodes of bipolar disorder were assigned to observation (n=42) and control group (n=39) according to different treatment methods ,both groups took orally SVSRT , observation was plus aripiprazole and control group plus quetiapine for 8 weeks .Manic states were as‐sessed with Young Mania Rating Scale (YMRS) ,qualities of life with the Short Form 36 Health Survey Questionnaire (SF‐36) ,sleep qualities with the Pittsburgh Sleep Quality Index (PSQI) ,and adverse reac‐tions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the total score of the YMRS and each dimension score of the PSQI of both groups lowered more significantly (P<0 .01) , those were significantly lower in observation than in control group (P<0 .01);each dimension scores of the SF‐36 of both groups heightened more significantly (P<0 .01) ,those were significantly higher in ob‐servation than in control group (P<0 .01) .Adverse reactions of both groups were mild ,their incidences had no significant group differences (P>0 .05) .Conclusion SVSRT plus aripiprazole in the treatment of manic episode of bipolar disorder has an evident effect and could effectively improve patients ’ quality of life and sleep quality .
展开▼
